Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xiufen Wang, Ying Wang, Li Luo, Liuting Tan, Wenzhi Cai, Ling Chen & Wei Ren. (2023) Prevalence and Associated Factors of Urinary Tract Infection in Patients with Diabetic Neuropathy: A Hospital-Based Cross-Sectional Study. Diabetes, Metabolic Syndrome and Obesity 16, pages 1261-1270.
Read now
Read now
Sarah Glover, Matthew E Borrego, Gretchen M Ray & Melissa H Roberts. (2022) Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis. ClinicoEconomics and Outcomes Research 14, pages 465-477.
Read now
Read now
Abhiroop Chakravarty, Mohini Rastogi, Praveen Dhankhar & Kelly F. Bell. (2018) Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics 21:5, pages 497-509.
Read now
Read now
Articles from other publishers (5)
Stephen P. Fortin, Joel Swerdel, Michal Sarnecki, Joachim Doua, Jamie Colasurdo & Jeroen Geurtsen. (2022) Performance characteristics of code‐based algorithms to identify urinary tract infections in large United States administrative claims databases. Pharmacoepidemiology and Drug Safety 31:9, pages 953-962.
Crossref
Crossref
Tadesse M. Abegaz, Vakaramoko Diaby, Fatimah Sherbeny & Askal Ayalew Ali. (2022) Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Clinical Drug Investigation 42:6, pages 501-511.
Crossref
Crossref
Ai-Yu Yang & Hung-Chun Chen. (2022) Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Journal of Diabetes Research 2022, pages 1-10.
Crossref
Crossref
Yao Wang, Xian Shao & Zewen Liu. (2022) Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly <i>versus</i> non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocrine Journal 69:6, pages 669-679.
Crossref
Crossref
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, Robert M. Gifford, Svenja Moser, Sarah H. Wild, Rebecca M. Reynolds, David J. Webb & Helen M. Colhoun. (2021) Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy 12:4, pages 991-1028.
Crossref
Crossref